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Abstract. 
Dihydroartemisinin–piperaquine (DP) is recommended for the treatment of uncomplicated malaria, used in 
efforts to contain artemisinin resistance, and increasingly considered for mass drug administration. Because of 
the narrow therapeutic dose range and available tablet strengths, the manufacturers and World Health 
Organization recommended regimens involve breaking tablets into halves to accurately dose children according 
to body weight. Use of tablet fractions in programmatic settings under tropical conditions requires a highly 
stable product; however, the stability of DP tablet fractions is unknown. We aged full and half DP (Eurartesim
®
) 
tablets in a stability chamber at 30°C and 70% humidity level. The active pharmaceutical ingredients 
dihydroartemisinin and piperaquine remained at  95% over the 3 months’ period of ageing in light and 
darkness. These findings are reassuring for DP, but highlight the need to assess drug stability under real-life 
settings during the drug development process, particularly for key drugs of global disease control programs. 
The antimalarial artemisinin-based combination therapy dihydroartemisinin–piperaquine 
(DP) is highly efficacious against uncomplicated malaria. Because of its long half-life and 
associated chemoprophylactic effect, DP is considered the most promising antimalarial for 
mass drug administration (MDA) for transmission reduction efforts in Africa.
1
 Furthermore, 
it is extensively studied for intermittent preventive treatment in children
2,3
 and pregnant 
women.
4,5
 The global discussion around use of drugs to reduce transmission has largely 
focused on DP’s pharmacokinetic and pharmacodynamic properties, and those of suitable 
gametocytocidal drugs, whereas more practical threats to successful implementation have 
received much less attention. 
Eurartesim, the only available fixed-dose combination of DP that has obtained marketing 
authorization from a stringent regulatory authority (i.e., the European Medicines Agency, 
[EMA]), is available as pediatric tablets containing 20 mg dihydroartemisinin and 160 mg 
piperaquine, and adult tablets containing 40 mg dihydroartemisinin and 320 mg piperaquine.
6
 
Due to the narrow therapeutic dose range and limited number of tablet strengths, the 
manufacturer
6
 and the World Health Organization (WHO)
7
 recommend breaking tablets into 
halves to accurately dosing children according to their body weight. There is no WHO 
guidance on age-based dose regimens, where the use of half tablets may help limit the 
substantial increase in dose intake variation. 
The major concern with tablet fractions, apart from inaccurate dosing resulting from 
imprecise breaking of tablets, is the intrinsic stability of broken tablets of DP under 
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conditions of high temperature and humidity found in malaria-endemic countries. Drug 
decomposition and formation of degradation products are typically accelerated in the 
presence of oxygen, moisture, heat, and strong light. As a consequence, remaining tablet 
halves may contain lower dose and, in the worst case, even toxic byproducts, potentially 
resulting in lack of clinical response, adverse events, and spread of antimalarial resistance. 
No data are available from the manufacturer, EMA registration, or scientific literature on the 
stability of DP tablet fractions once removed from the blister pack. In this study, we 
determined the stability of half tablets of DP at 37°C and 70% humidity as found in malaria-
endemic countries.
8
 The results address the gap in knowledge on the stability of tablet halves 
of DP and this crucial information will help the successful implementation of MDA programs 
using DP. 
Eurartesim (40/320 mg) tablets (N = 3601; Lot 141450; Exp 11/2016) were purchased 
from Manson’s Chemists Ltd (London E78BA, United Kingdom). Other chemicals were of 
high-performance liquid chromatography (HPLC) or analytical grade from various 
commercial sources. 
The short-term stability of DP tablets halves was investigated within their expiry date 
(January to April 2016) in a “natural ageing” study over 3 months’ light on (320–400 nm) 
and light off in climatic zone IV
9
 (30°C and 70% relative humidity) using a pharmaceutical 
stability chambers (PSC022, Weiss Gallenkamp, United Kingdom). Two hundred and forty 
tablets were manually split in half using as fragmentation of tablets was rather high when 
using a pill cutter. The halves were then put back in their blister. Supplemental Figures 1–7 
show the photos of tablets being broken manually and placed in the blister pack for ageing. 
Two hundred and forty halves were kept in light and 240 halves in darkness in the stability 
chamber. At defined time points, that is, 0 hours (= nonaged), 24 hours, 3 days, 1 calendar 
month, and 3 calendar months, 48 tablet halves from each light exposure group were removed 
(Table 1), and stored in their blister packs at 4°C until analysis (within 1 week of removal 
from the chamber). One hundred and twenty full tablets were used as controls (Table 1). 
Quantitative analysis of dihydroartemisinin and piperaquine was performed using a 
previously published HPLC with photo diode array detection method.
10
 Each full tablet or 
half tablet sample was dissolved in methanol first to obtain a 5 mg/mL solution of 
dihydroartemisinin. The sample was sonicated (10 minutes), 120 L removed, and 
centrifuged. The supernatant (10 L) was injected into the HPLC column and the amount of 
dihydroartemisinin present in the tablet was determined. To the rest of the solution 2 M HCl 
in methanol was added to obtain a 32 mg/mL stock solution of piperaquine, which was 
further diluted to get a 0.6 mg/mL dilute which was injected (20 L) onto the HPLC column. 
HPLC analysis was conducted using a Dionex Ultimate 3000 system (Thermofisher, Hemel 
Hempstead, UK) and for the analysis of piperaquine, separation achieved using a Acclaim 
120, C18, 5 m Analytical (4.6 × 150 mm, Fisher Scientific, Leicestershire, UK). The mobile 
phase was a gradient of ammonium formate (10 mM, pH 2.7) and acetonitrile (v/v; 15:85 to 
85:15 over 7.0 minutes). The separation of dihydroartemisinin was achieved using a 
GENESIS AQ 4 m column (150 × 4.6 mm, Grace Materials Technologies, Cranforth, UK). 
The mobile phase was a gradient of ammonium formate (10 mM, pH 2.7) and acetonitrile 
(v/v; 30:70 over 5.0 minutes). The photodiode array detector (UV-PDA; DAD 3000) was set 
at 204 nm for dihydroartemisinin and 360 nm for piperaquine. 
We tested the stability of Eurartesim full tablets and tablet halves when exposed to light 
or darkness at 30°C and 70% relative humidity for up to 3 months. The weights of tablets 
manually broken in half show the accuracy of this process (Table 2) and both, 
dihydroartemisinin and piperaquine amounts, remain fairly constant over 3 months in each 
group (Table 3). This addresses a key gap in implementation research, and reassures national 
malaria controls considering using DP for MDA as this will ensure the reduction of cost and 
wastage of unused tablet fractions. 
The International Conference on Harmonization and the WHO state that to properly 
assess long-term stability of finished pharmaceutical products, testing on how the quality of 
the product varies with time under the influence of temperature, humidity, and light should be 
conducted under storage conditions experienced in the intended market. A recent study found 
that full tablets of Coartem
®
 (artemether–lumefantrine) and ASAQ Winthrop® (artesunate–
amodiaqiuine) were stable when “naturally aged” under tropical conditions. Acceptable 
levels of all active pharmaceutical ingredients (90–110% as per international pharmacopeia 
tolerance limits) were measured over 3 years, despite drugs having reached their expiry dates 
within 18–24 months from the start of the study.11 
Information on the stability of tablet fractions is crucial especially when the number of 
available tablet strengths is limited to accurately dose all patient groups. In the case of DP, 
the manufacturer
6
 and the WHO
7
 recommend dosing regimen that, with the only available 
fixed-dose combination that has obtained marketing authorization from a stringent regulatory 
authority, can only be achieved by breaking tablets into halve. Although for individual 
treatment, caregivers can be advised to discard unused tablet fractions immediately after 
having administered the dose to the child to ensure no substandard tablets are administered 
during subsequent dosing time points, adherence to this strategy is not well known and seems 
even less feasible in an MDA setting where large quantities of wastage would be produced 
(with environmental and economic consequences). More information on stability of tablet 
fractions is therefore crucial for successful implementation of DP in programmatic settings as 
the knowledge base for drugs degraded as a result of storage in tropical climates is sparse at 
best
12–14
 and nonexistent for half tablets. 
Findings from our study are product specific and cannot be extrapolated to other DP 
brands or formulations. 
Information on stability of tablet fractions is crucial for successful implementation in 
programmatic settings, especially for drugs involving dosing recommendations based on 
tablet fractions in the absence of a child-friendly formulation. We recommend this type of 
information be collected much earlier in the drug development process and clearly stated on 
the package insert. 
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TABLE 1 
Number of tablets analyzed 
 Light Dark 
Exposure Full tablets Half tablets Full tablets Half tablets 
Nonaged 12 24 (48 × ½) 12 24 (48 × ½) 
24 hours 12 24 (48 × ½) 12 24 (48 × ½) 
3 days 12 24 (48 × ½) 12 24 (48 × ½) 
1 month 12 24 (48 × ½) 12 24 (48 × ½) 
3 months 12 24 (48 × ½) 12 24 (48 × ½) 
Total 60 120 (240 × ½) 60 120 (240 × ½) 
This table appears in color at www.ajtmh.org. 
TABLE 2 
Weight of tablets analyzed 
 Light Dark 
Exposure Full tablets Half tablets Full tablets Half tablets 
Nonaged 0.5318 (0.004)  0.2597 (0.016) 0.5332 (0.005) 0.2647 (0.011) 
24 hours 0.5315 (0.006) 0.2652 (0.010) 0.5306 (0.006) 0.2673 (0.019) 
3 days 0.5334 (0.006) 0.2684 (0.017) 0.5315 (0.003) 0.2677 (0.013) 
1 month 0.5361 (0.006) 0.2691 (0.010) 0.5336 (0.005) 0.2678 (0.012) 
3 months 0.5338 (0.004) 0.2678 (0.011) 0.5393 (0.006) 0.2671 (0.014) 
Mean weight in grams (standard deviation) for the numbers of tablets and tablet halves specified in Table 1. 
This table appears in color at www.ajtmh.org. 
TABLE 3 
Amounts of dihydroartemisinin (DHA) and piperaquine (PPQ) measured over time 
 
Light Dark 
 
Full tablets Half tablets Full tablets Half tablets 
Exposure DHA PPQ DHA PPQ DHA PPQ DHA PPQ 
Nonaged 
4.98 
(0.0039; 
99.6) 
0.60 
(0.0009; 
100.0) 
4.96 
(0.1249; 
99.1) 
0.58 
(0.0172; 
96.7) 
4.96 
(0.0648; 
99.2) 
0.60 
(0.0193; 
99.4) 
4.98 
(0.1133; 
99.6) 
0.60 
(0.009; 
99.8) 
24 hours 
4.99 
(0.1614; 
0.59 
(0.0126; 
4.96 
(0.1056; 
0.59 
(0.0179; 
4.96 
(0.1506; 
0.59 
(0.0160; 
4.97 
(0.7207; 
0.6 
(0.0932; 
99.9) 98.8) 99.2) 98.3) 99.4) 97.9) 99.4) 100.4) 
3 days 
4.94 
(0.1132; 
98.9) 
0.56 
(0.0258; 
93.1) 
4.93 
(0.1736; 
98.7) 
0.56 
(0.0312; 
93.9) 
4.96 
(0.0808; 
99.2) 
0.59 
(0.0148; 
98.5) 
4.96 
(0.0989; 
99.1) 
0.58 
(0.0250; 
99.8) 
1 month 
4.92 
(0.4742; 
98.4) 
0.56 
(0.0311; 
93.1) 
4.93 
(0.2359; 
98.7) 
0.57 
(0.0341; 
94.2) 
4.94 
(0.1184; 
98.8) 
0.58 
(0.0196; 
96.2) 
4.93 
(0.1404; 
98.7) 
0.57 
(0.0283; 
94.4) 
3 months 
4.90 
(0.0822; 
98.0) 
0.57 
(0.0216; 
95.4) 
4.92 
(0.1203; 
98.5) 
0.57 
(0.0272; 
95.8) 
4.91 
(0.0402; 
98.2) 
0.58 
(0.0032; 
96.1) 
4.90 
(0.2216; 
97.9) 
0.58 
(0.0294; 
97.1) 
Mean amount in mg/mL (SD; % active pharmaceutical ingredient) for the numbers of tablets and tablet halves 
specified in Table 1. This table appears in color at www.ajtmh.org. 
SUPPLEMENTAL FIGURE 1. Packets of Eurartesim 320 mg/40 mg used in the study. 
SUPPLEMENTAL FIGURE 2. Blister showing a tablet removed. 
SUPPLEMENTAL FIGURE 3. Manual tablet breaking. 
SUPPLEMENTAL FIGURE 4. Two tablet halves. 
SUPPLEMENTAL FIGURE 5. Tablet halves placed back in the blister. 
SUPPLEMENTAL FIGURE 6. Blister back in the packet with the tablet halves ready for ageing. 
SUPPLEMENTAL FIGURE 7. Boxes of full and half tablets in the stability chamber in presence (bottom) and 
absence (top) of light. 
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